Trials / Conditions / FLT3-mutated Acute Myeloid Leukemia
FLT3-mutated Acute Myeloid Leukemia
5 registered clinical trials studyying FLT3-mutated Acute Myeloid Leukemia.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Ac NCT05520567 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokineti NCT03591510 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patien NCT02829840 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnos NCT02310321 | Astellas Pharma Inc | Phase 1 / Phase 2 |
| No Longer Available | An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-d NCT03114228 | Novartis Pharmaceuticals | — |